Changing Dynamics Between NICE and Pharmaceutical Industry

Recent shifts in the UK’s National Institute for Health and Care Excellence’s (NICE) approach to health technology assessment (HTA) are encouraging a more collaborative relationship with the agency and the pharmaceutical industry. Earlier this year, NICE published their 5-year strategy entitled, “Dynamic, Collaborative, Excellent,” which laid out changes that encourage faster evaluation of technologies, dynamic guidelines, better guidance uptake, and thought leadership. In December, they will publish a new HTA manual.

According to Chris Poole and Keith Tolley at Xcenda, this manual will “evolve and broaden decision-making criteria, such as the introduction of disease severity modifiers that adjust quality-adjusted life-year thresholds for a range of diseases to replace end-of-life criteria that previously focused on cancer technologies. The changes will be reviewed in a future edition of HTA Quarterly.”

To learn more, click here.

(Source: Xcenda, AmerisourceBergen, October 20, 2021)